Know Cancer

forgot password

Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer

Phase 2
18 Years
Not Enrolling
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer

Thank you

Trial Information

Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer

OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression,
angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer.

II. Evaluate serum antibody levels and biologically active vascular endothelial growth
factor levels in the plasma of patients treated with this regimen.

III. Evaluate the toxicity of this regimen in these patients.

PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by prior
interleukin-2 therapy (yes vs no).

Patients are randomized to receive either placebo or one of two doses of monoclonal antibody
VEGF. Following an initial loading dose, patients receive one dose of the study drug
intravenously every 2 weeks for up to 2 years in the absence of disease progression.
Patients who are given placebo and experience disease progression are offered monoclonal
antibody VEGF and thalidomide if there are no contraindications.


A total of 150 patients will be accrued for this study over 2 years.

Inclusion Criteria


--Disease Characteristics-- Histologically proven unresectable advanced renal cell cancer
Measurable disease Must have received or not be a suitable candidate for interleukin-2
therapy No papillary or collecting duct renal cell cancer No CNS metastases
--Prior/Concurrent Therapy-- Biologic therapy: See Disease Characteristics No prior
thalidomide At least 4 weeks since other prior biologic therapy No other concurrent
biologic therapy Chemotherapy: At least 4 weeks since prior chemotherapy No concurrent
chemotherapy Endocrine therapy: At least 4 weeks since prior endocrine therapy No
concurrent corticosteroid therapy Radiotherapy: At least 4 weeks since prior radiotherapy
No concurrent radiotherapy Surgery: See Disease Characteristics --Patient
Characteristics-- Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least
6 months Hematopoietic: WBC at least 1,000/mm3 Platelet count at least 75,000/mm3 No
coagulation disorder, active bleeding, or wound healing problem Hepatic: Total bilirubin
no greater than 2.0 mg/dL (for patients with Gilbert's disease, direct bilirubin less than
0.5 mg/dL) SGOT or SGPT no greater than 3 times normal Renal: Creatinine no greater than
2.0 mg/dL Cardiovascular: No coronary artery disease Other: Not pregnant or nursing
Negative pregnancy test Fertile patients must use effective contraception No clinically
evident preexisting peripheral neuropathy

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

James Chung-Yin Yang

Investigator Role:

Study Chair

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

November 1998

Completion Date:

November 2004

Related Keywords:

  • Stage IV Renal Cell Cancer
  • Recurrent Renal Cell Cancer
  • adult solid tumor
  • body system/site cancer
  • cancer
  • kidney tumor
  • kidney/urinary cancer
  • recurrent renal cell cancer
  • renal cell cancer
  • solid tumor
  • stage IV renal cell cancer
  • stage, renal cell cancer
  • Carcinoma, Renal Cell



Surgery Branch Bethesda, Maryland  20892